| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.11 | 0.06 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.06 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.06 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.07 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.07 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |